Literature DB >> 7966070

Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients.

G Nesher1, M Sonnenblick, Y Friedlander.   

Abstract

OBJECTIVES: To analyze steroid related complications in patients with temporal arteritis (TA) and to evaluate their possible effect on survival.
METHODS: Forty-three consecutive patients with TA diagnosed in one center were followed over 10 years (mean 3 years). All were treated with prednisone. Clinical response and outcome, as well as prednisone dosage and adverse effects, were recorded throughout the followup period. A standardized mortality ratio (SMR) was calculated for the whole period.
RESULTS: Twenty-five patients (58%) developed major steroid related complications. The most common were fractures and severe infections. These complications were age related, occurring twice as often in patients older than 75 years compared to younger patients. Steroid related side effects were also dose related, occurring more commonly in patients starting with doses of > 40 mg/day and in patients taking high maintenance dosage. Nineteen patients died during the study period, 11 during the first year. Deaths of 7 patients were probably related to steroid treatment: Six had fatal infections and one had a fatal bleeding ulcer. The overall SMR was 2.12 (95% confidence interval 1.27-2.96), mainly due to excess mortality in the first year.
CONCLUSION: Steroid treatment in TA may cause major morbidity and increased mortality. The therapeutic regimen in TA should be individualized, and the patient's age, severity of TA, and coexistent medical conditions should be considered.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7966070

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  27 in total

Review 1.  Polymyalgia rheumatica/temporal arteritis: recent advances.

Authors:  Maria-Louise Barilla-LaBarca; Deborah J Lenschow; Richard D Brasington
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

Review 2.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

3.  Treatment of refractory temporal arteritis with adalimumab.

Authors:  M Mubashir Ahmed; Eisha Mubashir; Samina Hayat; Marjorie Fowler; Seth Mark Berney
Journal:  Clin Rheumatol       Date:  2006-08-30       Impact factor: 2.980

4.  Cough as the presenting symptom of large vessel vasculitis.

Authors:  B Van der Schueren; M Lambert
Journal:  Clin Rheumatol       Date:  2005-01-14       Impact factor: 2.980

5.  Infliximab as monotherapy in giant cell arteritis.

Authors:  Imad Uthman; Nadim Kanj; Samir Atweh
Journal:  Clin Rheumatol       Date:  2005-05-18       Impact factor: 2.980

Review 6.  Aortitis.

Authors:  Heather L Gornik; Mark A Creager
Journal:  Circulation       Date:  2008-06-10       Impact factor: 29.690

Review 7.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

8.  Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.

Authors:  Cristian Labarca; Matthew J Koster; Cynthia S Crowson; Ashima Makol; Steven R Ytterberg; Eric L Matteson; Kenneth J Warrington
Journal:  Rheumatology (Oxford)       Date:  2015-09-18       Impact factor: 7.580

9.  Overall and cause-specific mortality in giant cell arteritis : A meta-analysis.

Authors:  Y H Lee; G G Song
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.372

10.  Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.

Authors:  Tanaz A Kermani; Kenneth J Warrington; Cynthia S Crowson; Steven R Ytterberg; Gene G Hunder; Sherine E Gabriel; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.